Short fractionation radiotherapy for early prostate cancer in the time of COVID-19: long-term excellent outcomes from a multicenter Italian trial suggest a larger adoption in clinical practice.
Salvina BarraAlessia GuarnieriMichela Buglione di Monale E BastiaMichela MarcenaroElena TornariLiliana BelgioiaStefano Maria MagriniUmberto RicardiRenzo CorvòPublished in: La Radiologia medica (2020)
Stereotactic body radiotherapy for early prostate cancer reported safe toxicity profile and a good clinical outcome at the median follow-up of 5 years. It may be an useful option if radiotherapy is required in emergency medical conditions.
Keyphrases
- prostate cancer
- early stage
- locally advanced
- radical prostatectomy
- emergency medical
- clinical practice
- radiation induced
- radiation therapy
- coronavirus disease
- sars cov
- clinical trial
- oxidative stress
- squamous cell carcinoma
- randomized controlled trial
- phase iii
- electronic health record
- phase ii
- double blind
- open label